<p>對於 <strong>Chemours 公司</strong>（紐約證券交易所代碼：CC）股東來説，這一週表現平平，自最新季度財報發佈以來，股價下跌了 17%，至 22.41 美元。整體情況並不理想，儘管分析師原本預期會有盈利，但公司卻意外出現了每股 0.19 美元的法定虧損，營收為 14 億美元。財報發佈後，分析師們更新了他們的盈利模型，瞭解他們是否認為公司的前景發生了重大變化，或者一切如常，將會很有趣。我們認為讀者會對分析師最新的（法定）盈利預測感興趣，尤其是針對明年的預測。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行探索。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249061912-earnings-and-revenue-growth-1-dark-2/1778247092634?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249061912-earnings-and-revenue-growth-1-dark-2/1778247092634"/></p>
<p>紐約證券交易所：CC 盈利和收入增長 2026 年 5 月 8 日</p>
<p>考慮到最新的財報，Chemours 九位分析師的共識預測是 2026 年營收為 60.2 億美元。這反映出與過去 12 個月相比，營收有 3.5% 的適度改善。預計盈利將有所改善，Chemours 預計每股報告法定盈利 1.21 美元。在這份財報發佈之前，分析師們曾預測 2026 年營收為 60.4 億美元，每股盈利（EPS）為 1.58 美元。分析師們似乎在最新財報發佈後變得更加悲觀。雖然營收預測沒有變化，但每股盈利的預期卻大幅下調。</p>
<p>查看我們對 Chemours 的最新分析</p>
<p>儘管下調了盈利預測，分析師們仍將目標股價上調了 9.8%，至 24.89 美元，這表明這些影響預計不會在長期內對股價造成壓力。然而，從這些數據中我們可以得出其他結論，因為一些投資者在評估分析師的目標股價時也喜歡考慮預期的差異。最樂觀的 Chemours 分析師將目標股價定為每股 30.00 美元，而最悲觀的則為 17.00 美元。對於這隻股票，確實存在不同的看法，但我們認為預期範圍並不夠寬泛，以至於暗示情況無法預測。</p>
<p>我們還可以從更大的背景來看待這些預期，例如這些預測與過去表現的對比，以及相對於行業內其他公司的預測是否更為樂觀。例如，我們注意到 Chemours 的增長率預計將顯著加快，預計到 2026 年營收將以年均 4.6% 的速度增長。這遠高於過去五年每年 1.5% 的歷史下降率。相比之下，我們的數據表明，行業內其他公司（有分析師覆蓋）預計營收將以每年 5.2% 的速度增長。因此，儘管 Chemours 的營收預計將改善，但其增長速度似乎與整體行業大致相當。</p>
<h2>結論</h2>
<p>最重要的是，分析師下調了每股盈利的預期，顯示出在這些結果發佈後情緒明顯下降。他們還重新確認了營收預期，預計公司將以與更廣泛行業相似的速度增長。目標股價也有了不錯的提升，分析師們顯然認為公司的內在價值正在改善。</p>
<p>基於這一思路，我們認為公司的長期前景比明年的盈利更為重要。在 Simply Wall St，我們有 Chemours 到 2028 年的全系列分析師預估，您可以在我們的平台上免費查看。</p>
<p>話雖如此，仍然有必要考慮投資風險的潛在威脅。<strong>我們已識別出 Chemours 的 2 個警示信號</strong>（至少有 1 個讓我們感到不安），理解這些信號應成為您投資過程的一部分。</p>
<h3><strong>新：AI 股票篩選器和警報</strong></h3>
<p>我們的新 AI 股票篩選器每天掃描市場，發現機會。</p>
<p>• 分紅強勁的股票（收益率 3% 以上）</p>
<p>• 內部人士買入的被低估小盤股</p>
<p>• 高增長的科技和 AI 公司</p>
<p>或者從 50 多個指標中構建自己的篩選器。</p>
<p>立即免費探索</p>

<p>化工公司（Chemours Company，NYSE:CC）報告每股意外虧損 0.19 美元，營收為 14 億美元，導致股價下跌 17%。分析師已調整預測，預計 2026 年的營收為 60.2 億美元，每股收益為 1.21 美元，低於之前的預估。儘管盈利預期下調，目標股價仍上調 9.8% 至 24.89 美元，顯示出積極的長期前景。預計化工公司的增長速度將與行業平均水平相似，年營收增長率預計為 4.6%</p>

<p>It's been a mediocre week for <strong>The Chemours Company</strong> (NYSE:CC) shareholders, with the stock dropping 17% to US$22.41 in the week since its latest quarterly results. Things were not great overall, with a surprise (statutory) loss of US$0.19 per share on revenues of US$1.4b, even though the analysts had been expecting a profit. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.</p>
<div class="lb-trans"><p>對於 <strong>Chemours 公司</strong>（紐約證券交易所代碼：CC）股東來説，這一週表現平平，自最新季度財報發佈以來，股價下跌了 17%，至 22.41 美元。整體情況並不理想，儘管分析師原本預期會有盈利，但公司卻意外出現了每股 0.19 美元的法定虧損，營收為 14 億美元。財報發佈後，分析師們更新了他們的盈利模型，瞭解他們是否認為公司的前景發生了重大變化，或者一切如常，將會很有趣。我們認為讀者會對分析師最新的（法定）盈利預測感興趣，尤其是針對明年的預測。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行探索。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249061912-earnings-and-revenue-growth-1-dark-2/1778247092634" alt="" original-src="https://images.simplywall.st/asset/chart/249061912-earnings-and-revenue-growth-1-dark-2/1778247092634"/></p>
<p>NYSE:CC Earnings and Revenue Growth May 8th 2026</p>
<div class="lb-trans"><p>紐約證券交易所：CC 盈利和收入增長 2026 年 5 月 8 日</p>
</div><p>Taking into account the latest results, the consensus forecast from Chemours' nine analysts is for revenues of US$6.02b in 2026. This reflects an okay 3.5% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with Chemours forecast to report a statutory profit of US$1.21 per share. Before this earnings report, the analysts had been forecasting revenues of US$6.04b and earnings per share (EPS) of US$1.58 in 2026. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a pretty serious reduction to EPS estimates.</p>
<div class="lb-trans"><p>考慮到最新的財報，Chemours 九位分析師的共識預測是 2026 年營收為 60.2 億美元。這反映出與過去 12 個月相比，營收有 3.5% 的適度改善。預計盈利將有所改善，Chemours 預計每股報告法定盈利 1.21 美元。在這份財報發佈之前，分析師們曾預測 2026 年營收為 60.4 億美元，每股盈利（EPS）為 1.58 美元。分析師們似乎在最新財報發佈後變得更加悲觀。雖然營收預測沒有變化，但每股盈利的預期卻大幅下調。</p>
</div><p>Check out our latest analysis for Chemours</p>
<div class="lb-trans"><p>查看我們對 Chemours 的最新分析</p>
</div><p>Despite cutting their earnings forecasts,the analysts have lifted their price target 9.8% to US$24.89, suggesting that these impacts are not expected to weigh on the stock's value in the long term. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Chemours analyst has a price target of US$30.00 per share, while the most pessimistic values it at US$17.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.</p>
<div class="lb-trans"><p>儘管下調了盈利預測，分析師們仍將目標股價上調了 9.8%，至 24.89 美元，這表明這些影響預計不會在長期內對股價造成壓力。然而，從這些數據中我們可以得出其他結論，因為一些投資者在評估分析師的目標股價時也喜歡考慮預期的差異。最樂觀的 Chemours 分析師將目標股價定為每股 30.00 美元，而最悲觀的則為 17.00 美元。對於這隻股票，確實存在不同的看法，但我們認為預期範圍並不夠寬泛，以至於暗示情況無法預測。</p>
</div><p>Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. For example, we noticed that Chemours' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 4.6% growth to the end of 2026 on an annualised basis. That is well above its historical decline of 1.5% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 5.2% per year. So while Chemours' revenues are expected to improve, it seems that it is expected to grow at about the same rate as the overall industry.</p>
<div class="lb-trans"><p>我們還可以從更大的背景來看待這些預期，例如這些預測與過去表現的對比，以及相對於行業內其他公司的預測是否更為樂觀。例如，我們注意到 Chemours 的增長率預計將顯著加快，預計到 2026 年營收將以年均 4.6% 的速度增長。這遠高於過去五年每年 1.5% 的歷史下降率。相比之下，我們的數據表明，行業內其他公司（有分析師覆蓋）預計營收將以每年 5.2% 的速度增長。因此，儘管 Chemours 的營收預計將改善，但其增長速度似乎與整體行業大致相當。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>結論</h2>
</div><p>The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.</p>
<div class="lb-trans"><p>最重要的是，分析師下調了每股盈利的預期，顯示出在這些結果發佈後情緒明顯下降。他們還重新確認了營收預期，預計公司將以與更廣泛行業相似的速度增長。目標股價也有了不錯的提升，分析師們顯然認為公司的內在價值正在改善。</p>
</div><p>Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Chemours going out to 2028, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>基於這一思路，我們認為公司的長期前景比明年的盈利更為重要。在 Simply Wall St，我們有 Chemours 到 2028 年的全系列分析師預估，您可以在我們的平台上免費查看。</p>
</div><p>That said, it's still necessary to consider the ever-present spectre of investment risk. <strong>We've identified 2 warning signs</strong> with Chemours (at least 1 which doesn't sit too well with us) , and understanding these should be part of your investment process.</p>
<div class="lb-trans"><p>話雖如此，仍然有必要考慮投資風險的潛在威脅。<strong>我們已識別出 Chemours 的 2 個警示信號</strong>（至少有 1 個讓我們感到不安），理解這些信號應成為您投資過程的一部分。</p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：AI 股票篩選器和警報</strong></h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我們的新 AI 股票篩選器每天掃描市場，發現機會。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分紅強勁的股票（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 內部人士買入的被低估小盤股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增長的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者從 50 多個指標中構建自己的篩選器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免費探索</p>
</div>

Chemours 公司剛剛未能達到盈利預期，出現了意外虧損——以下是分析師的最新預測